Background: This study aimed to determine parameters for worsening oxygenation in mild COVID-19 pneumonia MESHD pneumonia HP.Methods: This retrospective cohort study included confirmed COVID-19 pneumonia MESHD pneumonia HP in a single public hospital in South Korea from January to April 2020. Parameters were compared between the two groups on the basis of clinical course: the desaturation group was defined as those with oxygen saturation ≤ 94% on ambient air, or received oxygen or mechanical ventilation (MV) throughout the clinical course versus the nonevent group who were without any respiratory event up to 28 days. The severity and extent of viral pneumonia MESHD pneumonia HP from an initial single chest CT were calculated using artificial intelligence (AI) algorithms and measured visually by a radiologist. Results: We included 136 patients with 32 (23.5%) in the desaturation group, of whom two needed MV and one died. Initial vital signs and duration of symptoms showed no difference between the two groups, however, univariate logistic regression analysis revealed that a variety of parameters at admission were associated with an increased risk of a desaturation event. In a sex-, age TRANS-, and comorbid illness-matched case-control study, ferritin ≥ 280 μg/L (OR 3.600, 95% CI 1.142-11.346; p=0.029), LDH≥ 240 U/L (OR 3.600, 95% CI 1.142-11.346; p=0.029), pneumonia MESHD pneumonia HP burden (OR 1.010, 95% CI 1.002-1.019; p=0.021), and extent (OR 1.194, 95% CI 1.017-1.401; p=0.030) by AI, and visual severity scores (OR 1.146, 95% CI 1.005-1.307; p=0.042) were the predictive parameters for worsening clinical course with desaturation. Conclusion: Our study presents initial CT parameters measured by AI or visual severity scoring as well as serum SERO markers of inflammation MESHD at admission as the best parameters for predicting worsening oxygenation in the COVID-19 pneumonia MESHD pneumonia HP cohort. Initial chest CT scans may help clinicians diagnose viral pneumonia MESHD pneumonia HP and evaluate the prognosis in mild COVID-19.